Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis

Endoscopy

Volumn 43, Issue 7, 2011, Pages 604-616

  Favre, L ^a   Borle, F ^b   Velin, D ^c   Bachmann, D ^c   Bouzourene, H ^c   Wagnieres, G ^b   Van Den Bergh, H ^b   Ballabeni, P ^d   Gabrecht, T ^b   Michetti, P ^c   Schreiber, S ^e   Ortner, M A ^f  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b EPFL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 6; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; COLITIS; COLONOSCOPY; CONTROLLED STUDY; DISEASE MODEL; IN VIVO STUDY; LOW DOSE PHOTODYNAMIC THERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE BLIND PROCEDURE;

AMINOLEVULINIC ACID; ANIMALS; APOPTOSIS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COLITIS; COLONOSCOPY; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED BALB C; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 79959848257     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/s-0030-1256382     Document Type: Article

References (64)

1. Kucharzik T, Maaser C, Lügering A et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006 12 1068-1083
2. Young Y, Abreu M T. Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep 2006 8 470-477 (Pubitemid 46017159)
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007 117 514-521 (Pubitemid 46348505)
4. Xavier R J., Podolsky D K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007 448 427-434 (Pubitemid 47123518)
5. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006 116 1218-1222
6. Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006 116 1310-1316
7. Duerr R H., Taylor K D., Brant S R. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006 314 1461-1463 (Pubitemid 44871953)
8. Sturm A, Fiocchi C. Life and death in the gut: more killing, less Crohns. Gut 2002 50 148-149 (Pubitemid 34087922)
9. Danese S, Sans M, de la Motte C et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006 130 2060-2073 (Pubitemid 43816964)
10. Targan S R. Current limitations of IBD treatment: where do we go from here? Ann NY Acad Sci 2006 1072 1-8 (Pubitemid 44448438)
11. Colombel J F., Sandborn W J., Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial. Gastroenterology 2007 132 52-65 (Pubitemid 46108762)
12. Hanauer S B., Feagan B G., Lichtenstein G R. et al. ACCENT I Study Group. Maintenance infliximab for Crohns disease: The ACCENT I randomized trial. Lancet 2002 359 1541-1549 (Pubitemid 34621118)
13. Schreiber S, Khaliq-Kareemi M, Lawrence I C. et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohns disease. NEJM 2007 357 239-250 (Pubitemid 47080388)
14. Baert F, Norman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. NEJM 2003 348 601-608 (Pubitemid 36204954)
15. Aksamit A J. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist 2006 12 293-298 (Pubitemid 44813665)
16. Rychly D J., DiPiro J T. Infection associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005 25 1181-1192 (Pubitemid 41242578)
17. Mackey A C., Green L, Liang L C. et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 44 265-267 (Pubitemid 46175082)
18. Ortner M, Caca K, Berr F et al. Photodynamic therapy for non-resectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003 125 1355-1363 (Pubitemid 37409755)
19. Eleouet S, Carre J, Vonarx V et al. Delta-aminolevulinic acid-induced fluorescence in normal human lymphocytes. J Photochem Photobiol B 1997 41 22-29 (Pubitemid 28010573)
20. Hunt D W., Jiang H, Granville D J. et al. Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharmacology 1999 41 31-44 (Pubitemid 29044108)
21. Jiang H, Granville D J., North J R. et al. Selective action of the photosensitizer QLT0074 on activated human T lymphocytes. Photochem Photobiol 2002 76 224-231
22. Hryhorenko E A., Oseroff A R., Morgan J et al. Deletion of alloantigen-activated cells by aminolevulinic acid-based photodynamic therapy. Photochem Photobiol 1999 69 560-565 (Pubitemid 129555476)
23. Bissonnette R, Tremblay J F., Juzenas P et al. Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T-lymphocytes of psoriatic plaques. J Invest Dermatol 2002 119 77-83 (Pubitemid 35304394)
24. Hunt D W., Chan A H. Influence of photodynamic therapy on immunological aspects of disease an update. Expert Opin Investig Drugs 2000 9 807-817 (Pubitemid 30175647)
25. Musser D A., Oseroff A R. Characteristics of the immunosuppression induced by cutaneous photodynamic therapy: persistence, antigen specificity and cell type involved. Photochem Photobiol 2001 73 518-524 (Pubitemid 33720365)
26. Simkin G O., Tao J S., Lervy J G. et al. IL-10 contributes to the inhibition of contact hypersensitivity in mice treated with photodynamic therapy. J Immunol 2000 164 2457-2462 (Pubitemid 30115474)
27. Jori G. Photodynamic therapy of microbial infections: state of the art and perspectives. J Environ Pathol Toxicol Oncol 2006 25 505-519 (Pubitemid 43341261)
28. Pegaz B, Debefve E, Borle F et al. Preclinical evaluation of a novel water-soluble chlorin E6 derivate (BLC 1010) as photosensitizer for the closure of the neovessels. Photochem Photobiol 2005 81 1505-1510 (Pubitemid 43035864)
29. Boehncke W H., Elshorst-Schmidt T, Kaufmann R. Systemic photodynamic therapy is a safe and effective treatment of psoriasis. Arch Dermatol 2000 136 271-272 (Pubitemid 30090777)
30. Funke B, Jungel A, Schastak S et al. Transdermal photodynamic therapy a treatment option for rheumatoid destruction of small joints? Lasers Surg Med 2006 38 866-874 (Pubitemid 44706592)
31. Ratkay L G., Chowdhary R K., Iamaroon A et al. Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. Arthritis Rheum 1998 41 525-534 (Pubitemid 28128778)
32. Chowdhary R K., Ratkay L G., Neyndorff H C. et al. The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice. Clin Immunol Immunopathol 1994 72 255-263 (Pubitemid 24259444)
33. Ratkay L G., Chowdhary R K., Neyendorff H C. et al. Photodynamic therapy: A comparison with other immunomodulatory treatments of adjuvant-enhanced arthritis in MRL-lpr mice. Clin Exp Immunol 1994 95 373-377 (Pubitemid 24210176)
34. Hunt D W., Jiang H, Granville D J. et al. Consequence of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharmacology 1999 41 31-44 (Pubitemid 29044108)
35. Saripalli Y V., Gaspari A A. Focus on: biologicals that affect therapeutic agents in dermatology. J Drugs Dermatol 2005 4 233-245
36. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004 202 250-265 (Pubitemid 39576917)
37. Powrie F, Leach M W., Mauze S et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 SCID mice. Int Immunol 1993 5 1461-1471 (Pubitemid 23325202)
38. Kirdaite G, Lange N, Busso N et al. Protoporphyrin IX photodynamic therapy for synovitis. Arthritis Rheum 2002 46 1371-1378 (Pubitemid 34525847)
39. Fukuda H, Casas A, Batlle A. Aminolaevulinic acid: from its unique biological function to its star role in photodynamic therapy. Int J Biochem Cell Biol 2005 37 272-276 (Pubitemid 39330188)
40. Wirtz S, Becker C, Blumberg R et al. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 2002 168 411-420 (Pubitemid 34014143)
41. Wächtershäuser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr 2000 39 164-171
42. Verdu E F., Bercik B, Cukrowska B et al. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin Exp Immunol 2000 120 46-50 (Pubitemid 30176898)
43. Vermes I, Haanen C, Steffens-Nakken H et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995 184 39-51
44. DHaens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumour necrosis factor antibodies in Crohns Disease. A European multicenter trial. Gastroenterology 1999 116 1029-1034 (Pubitemid 29203012)
45. Fossiez F, Banchereau J, Murray R et al. Interleukin-17. Int Rev Immunol 1998 16 541-551 (Pubitemid 28286184)
46. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003 52 65-70 (Pubitemid 36020767)
47. Langrish C L., Chen Y, Blumenschein W M. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 201 233-240 (Pubitemid 40189432)
48. Becker C, Dornhoff H, Neufert C et al. Cutting edge: Il-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 2006 177 2760-2764 (Pubitemid 44277789)
49. Hunt D W., Chan A H. Immunological aspects of photodynamic therapy. Photodynamic News 1998 1 2-4
50. Yusuf N, Katiyar S K., Elmets C A. The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4+ and CD8+ T cells and can be adoptively transferred to naïve recipients. Photochem Photobiol 2008 84 366-370 (Pubitemid 351421387)
51. Hryhorenko E A., Rittenhouse-Diakun K, Harvey N S. et al. Characterization of endogenous protoporphyrin IX induced by delta-aminolevulinic acid in resting and activated peripheral blood lymphocytes by four-color flow cytometry. Photochem Photobiol 1998 67 565-572 (Pubitemid 128472282)
52. Granville D J., Carthy C M., Jiang H et al. Nuclear-factor-kappa B activation by the photochemotherapeutic agent verteporfin. Blood 2000 95 256-262 (Pubitemid 30017250)
53. Kessel D, Luo Y. Photodynamic therapy: a mitochondrial inducer of apoptosis. Cell Death Differ 1999 6 28-35 (Pubitemid 29051852)
54. Granville D J., Jiang H, An M T. et al. Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy. Br J Cancer 1999 79 95-100 (Pubitemid 28566932)
55. Itoh J, de la Motte C, Strong S A. et al. Decreased Bax expression by mucosal T cells favors resistance to apoptosis in Crohns disease (CD). Gut 2001 49 35-41 (Pubitemid 32601877)
56. Jiang H, Granville D J., McManus B M. et al. Selective depletion of a thymocyte subset in vitro with an immunomodulatory photosensitizer. Clin Immunol 1999 91 178-187 (Pubitemid 29203417)
57. Lugering A, Lebiedz P, Koch S et al. Apoptosis as a therapeutic tool in IBD? Ann NY Acad Sci 2006 1072 62-77
58. Ina K, Itoh J, Fukushima K et al. Resistance of Crohns disease T-cells to multiple apoptotic stimuli is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999 163 1081-1090 (Pubitemid 29328123)
59. Hryhorenko E A., Oseroff A R., Morgan J et al. Antigen specific and nonspecific modulation of the immune response by aminolevulinic acid based photodynamic therapy. Immunopharmacology 1998 40 231-240 (Pubitemid 28522181)
60. Wong T W., Tracy E, Oseroff A R. et al. Photodynamic therapy mediates immediate loss of cellular responsiveness to cytokines and growth factors. Cancer Res 2003 63 3812-3818 (Pubitemid 36793071)
61. King D E., Jiang H, Simkin G O. et al. Photodynamic alteration on the surface receptor expression pattern of murine splenic dendritic cells. Scand J Immunol 1999 49 184-192 (Pubitemid 29096315)
62. Panjehpour M, Overholt B F., Phan M N. et al. Optimization of light dosimetry for photodynamic therapy of Barretts esophagus: efficacy vs. incidence of stricture after treatment. Gastrointestinal Endosc 2005 61 13-18 (Pubitemid 40169805)
63. Perry Y, Epperly M W., Fernando H C. et al. Photodynamic therapy induced esophageal stricture an animal model: from mouse to pig. J Surg Res 2005 123 67-74 (Pubitemid 40094646)
64. Mackenzie G D., Jamieson N F., Novelli M R. et al. How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barretts esophagus. Lasers Med Sci 2008 23 203-210 (Pubitemid 351422641)